In this section, we usually try to help investors determine whether Entia Biosciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Entia Biosciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway